Skip to main content
Top
Published in: Virology Journal 1/2023

Open Access 01-12-2023 | SARS-CoV-2 | Research

Angiotensin-converting enzyme 2 (ACE2) polymorphisms and susceptibility of severe SARS-CoV-2 in a subset of Pakistani population

Authors: Santosh Kumar Sidhwani, Talat Mirza, Ambrina Khatoon, Fouzia Shaikh, Rizma Khan, Omer Ahmed Shaikh, Abdulqadir J. Nashwan

Published in: Virology Journal | Issue 1/2023

Login to get access

Abstract

Science is digging for the varied presentation of COVID-19 patients exposed to the same risk factors, and medical conditions may be influenced by the presence of polymorphic genetic variants. This study investigated the link between ACE2 gene polymorphisms and the severity of SARS-CoV-2. This cross-sectional study recruited COVID-19 PCR-positive patients by consecutive sampling from Ziauddin Hospital from April to September 2020. DNA was extracted from whole blood, followed by gene amplification and Sanger’s sequencing. Most of the patients, 77: 53.8%, were serious. Males were higher (80; 55.9%) with age more than 50 years (106: 74.1%). We found 22 ACE2 SNPs. rs2285666 SNP was most prevalent with 49.2% CC, 45.2% TT, 4.8% CT heterozygosity, and 0.8% AA genotypes. Variants with multiple genotypes were also insignificantly associated with the severity of COVID-19 in the analysis of the dominant model. Only rs2285666 had a significant statistical link with gender (p-value 0.034, OR; 1.438, CI; 1.028–2.011) while rs768883316 with age groups (p-value 0.026, OR; 1.953, CI; 1.085–3.514). Haplotypes ATC of three polymorphisms (rs560997634, rs201159862, and rs751170930) commonly found in 120 (69.77%) and TTTGTAGTTAGTA haplotype consisting of 13 polymorphisms (rs756737634, rs146991645, rs1601703288, rs1927830489, rs1927831624, rs764947941, rs752242172, rs73195521, rs781378335, rs756597390, rs780478736, rs148006212, rs768583671) in 112 (90.32%) had statistically significant association with the severity having p = value 0.029 and 0.001 respectively. Males of old age and diabetics are found to have more severe COVID-19 infection in the current study. We also found that common ACE2 polymorphism rs2285666 influences the susceptibility of acquiring the severe SARS-CoV-2 infection.
Appendix
Available only for authorised users
Literature
1.
go back to reference Team GAC-G, Landi F, Barillaro C, Bellieni A, Brandi V, Carfì A, et al. The new challenge of geriatrics: saving frail older people from the SARS-COV-2 pandemic infection. J Nutr Health Aging. 2020;24:466–70.CrossRef Team GAC-G, Landi F, Barillaro C, Bellieni A, Brandi V, Carfì A, et al. The new challenge of geriatrics: saving frail older people from the SARS-COV-2 pandemic infection. J Nutr Health Aging. 2020;24:466–70.CrossRef
2.
go back to reference Huang NX, Yuan Q, Fang F, Yan BP, Sanderson JE. Systematic review and meta-analysis of the clinical outcomes of ACEI/ARB in East-Asian patients with COVID-19. PLoS ONE. 2023;18(1):e0280280.CrossRefPubMedPubMedCentral Huang NX, Yuan Q, Fang F, Yan BP, Sanderson JE. Systematic review and meta-analysis of the clinical outcomes of ACEI/ARB in East-Asian patients with COVID-19. PLoS ONE. 2023;18(1):e0280280.CrossRefPubMedPubMedCentral
3.
go back to reference Ragia G, Manolopoulos VG. Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies. Eur J Clin Pharmacol. 2020;76:1623–30.CrossRefPubMedPubMedCentral Ragia G, Manolopoulos VG. Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies. Eur J Clin Pharmacol. 2020;76:1623–30.CrossRefPubMedPubMedCentral
4.
go back to reference Beeraka NM, Sadhu SP, Madhunapantula SV, Rao Pragada R, Svistunov AA, Nikolenko VN, et al. Strategies for targeting sars cov-2: small molecule inhibitors—the current status. Front Immunol. 2020;11:552925.CrossRefPubMedPubMedCentral Beeraka NM, Sadhu SP, Madhunapantula SV, Rao Pragada R, Svistunov AA, Nikolenko VN, et al. Strategies for targeting sars cov-2: small molecule inhibitors—the current status. Front Immunol. 2020;11:552925.CrossRefPubMedPubMedCentral
5.
go back to reference Latil M, Camelo S, Veillet S, Lafont R, Dilda PJ. Developing new drugs that activate the protective arm of the renin–angiotensin system as a potential treatment for respiratory failure in COVID-19 patients. Drug Discovery Today. 2021;26(5):1311–8.CrossRefPubMedPubMedCentral Latil M, Camelo S, Veillet S, Lafont R, Dilda PJ. Developing new drugs that activate the protective arm of the renin–angiotensin system as a potential treatment for respiratory failure in COVID-19 patients. Drug Discovery Today. 2021;26(5):1311–8.CrossRefPubMedPubMedCentral
6.
go back to reference Orooji Y, Sohrabi H, Hemmat N, Oroojalian F, Baradaran B, Mokhtarzadeh A, et al. An overview on SARS-CoV-2 (COVID-19) and other human coronaviruses and their detection capability via amplification assay, chemical sensing, biosensing, immunosensing, and clinical assays. Nano-micro Lett. 2021;13:1–30.CrossRef Orooji Y, Sohrabi H, Hemmat N, Oroojalian F, Baradaran B, Mokhtarzadeh A, et al. An overview on SARS-CoV-2 (COVID-19) and other human coronaviruses and their detection capability via amplification assay, chemical sensing, biosensing, immunosensing, and clinical assays. Nano-micro Lett. 2021;13:1–30.CrossRef
7.
go back to reference Sabater Molina M, Nicolás Rocamora E, Bendicho AI, Vázquez EG, Zorio E, Rodriguez FD, et al. Polymorphisms in ACE, ACE2, AGTR1 genes and severity of COVID-19 disease. PLoS ONE. 2022;17(2):e0263140.CrossRefPubMedPubMedCentral Sabater Molina M, Nicolás Rocamora E, Bendicho AI, Vázquez EG, Zorio E, Rodriguez FD, et al. Polymorphisms in ACE, ACE2, AGTR1 genes and severity of COVID-19 disease. PLoS ONE. 2022;17(2):e0263140.CrossRefPubMedPubMedCentral
8.
go back to reference Covid C, Team R, Bialek S, Boundy E, Bowen V, Chow N. Severe outcomes among patients with coronavirus disease 2019 (COVID-19)—United States, February 12–March 16, 2020. Morb Mortal Wkly Rep. 2020;69(12):343.CrossRef Covid C, Team R, Bialek S, Boundy E, Bowen V, Chow N. Severe outcomes among patients with coronavirus disease 2019 (COVID-19)—United States, February 12–March 16, 2020. Morb Mortal Wkly Rep. 2020;69(12):343.CrossRef
9.
go back to reference Lippi G, Lavie CJ, Henry BM, Sanchis-Gomar F. Do genetic polymorphisms in angiotensin converting enzyme 2 (ACE2) gene play a role in coronavirus disease 2019 (COVID-19)? Clinical Chemistry and Laboratory Medicine (CCLM). 2020;58(9):1415–22. Lippi G, Lavie CJ, Henry BM, Sanchis-Gomar F. Do genetic polymorphisms in angiotensin converting enzyme 2 (ACE2) gene play a role in coronavirus disease 2019 (COVID-19)? Clinical Chemistry and Laboratory Medicine (CCLM). 2020;58(9):1415–22.
10.
go back to reference McIntosh K, Perlman S. Coronaviruses, including severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). Mandell, douglas, and bennett’s principles and practice of infectious diseases. 2015:1928. McIntosh K, Perlman S. Coronaviruses, including severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). Mandell, douglas, and bennett’s principles and practice of infectious diseases. 2015:1928.
11.
go back to reference Asselta R, Paraboschi EM, Mantovani A, Duga S. ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy. Aging. 2020;12(11):10087.CrossRefPubMedPubMedCentral Asselta R, Paraboschi EM, Mantovani A, Duga S. ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy. Aging. 2020;12(11):10087.CrossRefPubMedPubMedCentral
12.
go back to reference Ciaglia E, Vecchione C, Puca AA. COVID-19 infection and circulating ACE2 levels: protective role in women and children. Front Pead. 2020;8:206.CrossRef Ciaglia E, Vecchione C, Puca AA. COVID-19 infection and circulating ACE2 levels: protective role in women and children. Front Pead. 2020;8:206.CrossRef
13.
go back to reference Liu Y, Mao B, Liang S, Yang J-W, Lu H-W, Chai Y-H et al. Association between age and clinical characteristics and outcomes of COVID-19. Eur Respir J. 2020;55(5). Liu Y, Mao B, Liang S, Yang J-W, Lu H-W, Chai Y-H et al. Association between age and clinical characteristics and outcomes of COVID-19. Eur Respir J. 2020;55(5).
14.
go back to reference Cheng H, Wang Y, Wang GQ. Organ-protective effect of angiotensin‐converting enzyme 2 and its effect on the prognosis of COVID‐19. J Med Virol. 2020;92(7):726–30.CrossRefPubMedPubMedCentral Cheng H, Wang Y, Wang GQ. Organ-protective effect of angiotensin‐converting enzyme 2 and its effect on the prognosis of COVID‐19. J Med Virol. 2020;92(7):726–30.CrossRefPubMedPubMedCentral
15.
go back to reference Parit R, Jayavel S. Association of ACE inhibitors and angiotensin type II blockers with ACE2 overexpression in COVID-19 comorbidities: a pathway-based analytical study. Eur J Pharmacol. 2021;896:173899.CrossRefPubMedPubMedCentral Parit R, Jayavel S. Association of ACE inhibitors and angiotensin type II blockers with ACE2 overexpression in COVID-19 comorbidities: a pathway-based analytical study. Eur J Pharmacol. 2021;896:173899.CrossRefPubMedPubMedCentral
16.
go back to reference Beyerstedt S, Casaro EB, Rangel ÉB. COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. Eur J Clin Microbiol Infect Dis. 2021;40(5):905–19.CrossRefPubMedPubMedCentral Beyerstedt S, Casaro EB, Rangel ÉB. COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. Eur J Clin Microbiol Infect Dis. 2021;40(5):905–19.CrossRefPubMedPubMedCentral
17.
go back to reference Horowitz JE, Kosmicki JA, Damask A, Sharma D, Roberts GH, Justice AE, et al. Genome-wide analysis provides genetic evidence that ACE2 influences COVID-19 risk and yields risk scores associated with severe disease. Nat Genet. 2022;54(4):382–92.CrossRefPubMedPubMedCentral Horowitz JE, Kosmicki JA, Damask A, Sharma D, Roberts GH, Justice AE, et al. Genome-wide analysis provides genetic evidence that ACE2 influences COVID-19 risk and yields risk scores associated with severe disease. Nat Genet. 2022;54(4):382–92.CrossRefPubMedPubMedCentral
18.
go back to reference Patel P, Hiam L, Sowemimo A, Devakumar D, McKee M. Ethnicity and covid-19. British Medical Journal Publishing Group; 2020. Patel P, Hiam L, Sowemimo A, Devakumar D, McKee M. Ethnicity and covid-19. British Medical Journal Publishing Group; 2020.
19.
go back to reference Al-Mulla F, Mohammad A, Al Madhoun A, Haddad D, Ali H, Eaaswarkhanth M, et al. ACE2 and FURIN variants are potential predictors of SARS-CoV-2 outcome: a time to implement precision medicine against COVID-19. Heliyon. 2021;7(2):e06133.CrossRefPubMedPubMedCentral Al-Mulla F, Mohammad A, Al Madhoun A, Haddad D, Ali H, Eaaswarkhanth M, et al. ACE2 and FURIN variants are potential predictors of SARS-CoV-2 outcome: a time to implement precision medicine against COVID-19. Heliyon. 2021;7(2):e06133.CrossRefPubMedPubMedCentral
20.
go back to reference Calcagnile M, Forgez P, Iannelli A, Bucci C, Alifano M, Alifano P. ACE2 polymorphisms and individual susceptibility to SARS-CoV-2 infection: insights from an in silico study. BioRxiv. 2020. Calcagnile M, Forgez P, Iannelli A, Bucci C, Alifano M, Alifano P. ACE2 polymorphisms and individual susceptibility to SARS-CoV-2 infection: insights from an in silico study. BioRxiv. 2020.
21.
go back to reference Srivastava A, Bandopadhyay A, Das D, Pandey RK, Singh V, Khanam N et al. Genetic association of ACE2 rs2285666 polymorphism with COVID-19 spatial distribution in India. Front Genet. 2020:1163. Srivastava A, Bandopadhyay A, Das D, Pandey RK, Singh V, Khanam N et al. Genetic association of ACE2 rs2285666 polymorphism with COVID-19 spatial distribution in India. Front Genet. 2020:1163.
22.
go back to reference Gemmati D, Bramanti B, Serino ML, Secchiero P, Zauli G, Tisato V. COVID-19 and individual genetic susceptibility/receptivity: role of ACE1/ACE2 genes, immunity, inflammation and coagulation. Might the double X-chromosome in females be protective against SARS-CoV-2 compared to the single X-chromosome in males? Int J Mol Sci. 2020;21(10):3474.CrossRefPubMedPubMedCentral Gemmati D, Bramanti B, Serino ML, Secchiero P, Zauli G, Tisato V. COVID-19 and individual genetic susceptibility/receptivity: role of ACE1/ACE2 genes, immunity, inflammation and coagulation. Might the double X-chromosome in females be protective against SARS-CoV-2 compared to the single X-chromosome in males? Int J Mol Sci. 2020;21(10):3474.CrossRefPubMedPubMedCentral
23.
go back to reference Wooster L, Nicholson CJ, Sigurslid HH, Lino Cardenas CL, Malhotra R. Polymorphisms in the ACE2 locus associate with severity of COVID-19 infection. MedRxiv. 2020:2020.06. 18.20135152. Wooster L, Nicholson CJ, Sigurslid HH, Lino Cardenas CL, Malhotra R. Polymorphisms in the ACE2 locus associate with severity of COVID-19 infection. MedRxiv. 2020:2020.06. 18.20135152.
24.
go back to reference Alimoradi N, Sharqi M, Firouzabadi D, Sadeghi MM, Moezzi MI, Firouzabadi N. SNPs of ACE1 (rs4343) and ACE2 (rs2285666) genes are linked to SARS-CoV-2 infection but not with the severity of disease. Virol J. 2022;19(1):1–9.CrossRef Alimoradi N, Sharqi M, Firouzabadi D, Sadeghi MM, Moezzi MI, Firouzabadi N. SNPs of ACE1 (rs4343) and ACE2 (rs2285666) genes are linked to SARS-CoV-2 infection but not with the severity of disease. Virol J. 2022;19(1):1–9.CrossRef
25.
go back to reference Bosso M, Thanaraj TA, Abu-Farha M, Alanbaei M, Abubaker J, Al-Mulla F. The two faces of ACE2: the role of ACE2 receptor and its polymorphisms in hypertension and COVID-19. Mol Therapy-Methods Clin Dev. 2020;18:321–7.CrossRef Bosso M, Thanaraj TA, Abu-Farha M, Alanbaei M, Abubaker J, Al-Mulla F. The two faces of ACE2: the role of ACE2 receptor and its polymorphisms in hypertension and COVID-19. Mol Therapy-Methods Clin Dev. 2020;18:321–7.CrossRef
26.
go back to reference Karakaş Çelik S, Çakmak Genç G, Pişkin N, Açikgöz B, Altinsoy B, Kurucu İşsiz B, et al. Polymorphisms of ACE (I/D) and ACE2 receptor gene (Rs2106809, Rs2285666) are not related to the clinical course of COVID-19: a case study. J Med Virol. 2021;93(10):5947–52.CrossRefPubMedPubMedCentral Karakaş Çelik S, Çakmak Genç G, Pişkin N, Açikgöz B, Altinsoy B, Kurucu İşsiz B, et al. Polymorphisms of ACE (I/D) and ACE2 receptor gene (Rs2106809, Rs2285666) are not related to the clinical course of COVID-19: a case study. J Med Virol. 2021;93(10):5947–52.CrossRefPubMedPubMedCentral
27.
go back to reference Huang W, Yang W, Wang Y, Zhao Q, Gu D, Chen R. Association study of angiotensin-converting enzyme 2 gene (ACE2) polymorphisms and essential hypertension in northern Han Chinese. J Hum Hypertens. 2006;20(12):968–71.CrossRefPubMed Huang W, Yang W, Wang Y, Zhao Q, Gu D, Chen R. Association study of angiotensin-converting enzyme 2 gene (ACE2) polymorphisms and essential hypertension in northern Han Chinese. J Hum Hypertens. 2006;20(12):968–71.CrossRefPubMed
28.
go back to reference Saengsiwaritt W, Jittikoon J, Chaikledkaew U, Udomsinprasert W. Genetic polymorphisms of ACE1, ACE2, and TMPRSS2 associated with COVID-19 severity: a systematic review with meta‐analysis. Rev Med Virol. 2022:e2323. Saengsiwaritt W, Jittikoon J, Chaikledkaew U, Udomsinprasert W. Genetic polymorphisms of ACE1, ACE2, and TMPRSS2 associated with COVID-19 severity: a systematic review with meta‐analysis. Rev Med Virol. 2022:e2323.
29.
go back to reference Çelik SK, Genç G, Piskin N, Acikgoz B, Altınsoy B, İşsiz BK et al. ACE I/D and ACE2 receptor gene (RS2106809, RS2285666) polymorphisms is not related to the clinical course of COVID-19; a case study. Authorea Preprints. 2021. Çelik SK, Genç G, Piskin N, Acikgoz B, Altınsoy B, İşsiz BK et al. ACE I/D and ACE2 receptor gene (RS2106809, RS2285666) polymorphisms is not related to the clinical course of COVID-19; a case study. Authorea Preprints. 2021.
30.
go back to reference Choudhary S, Sreenivasulu K, Mitra P, Misra S, Sharma P. Role of genetic variants and gene expression in the susceptibility and severity of COVID-19. Annals of laboratory medicine. 2021;41(2):129–38.CrossRefPubMedPubMedCentral Choudhary S, Sreenivasulu K, Mitra P, Misra S, Sharma P. Role of genetic variants and gene expression in the susceptibility and severity of COVID-19. Annals of laboratory medicine. 2021;41(2):129–38.CrossRefPubMedPubMedCentral
31.
go back to reference Khoury MJ, Beaty TH, Cohen BH. Fundamentals of genetic epidemiology: Monographs in Epidemiology and; 1993. Khoury MJ, Beaty TH, Cohen BH. Fundamentals of genetic epidemiology: Monographs in Epidemiology and; 1993.
32.
go back to reference Yamamoto N, Nishida N, Yamamoto R, Gojobori T, Shimotohno K, Mizokami M, et al. Angiotensin–converting enzyme (ACE) 1 gene polymorphism and phenotypic expression of COVID-19 symptoms. Genes. 2021;12(10):1572.CrossRefPubMedPubMedCentral Yamamoto N, Nishida N, Yamamoto R, Gojobori T, Shimotohno K, Mizokami M, et al. Angiotensin–converting enzyme (ACE) 1 gene polymorphism and phenotypic expression of COVID-19 symptoms. Genes. 2021;12(10):1572.CrossRefPubMedPubMedCentral
33.
go back to reference Pouladi N, Abdolahi S. Investigating the ACE2 polymorphisms in COVID-19 susceptibility: an in silico analysis. Mol Genet Genom Med. 2021;9(6):e1672. Pouladi N, Abdolahi S. Investigating the ACE2 polymorphisms in COVID-19 susceptibility: an in silico analysis. Mol Genet Genom Med. 2021;9(6):e1672.
34.
go back to reference Huffman JE, Butler-Laporte G, Khan A, Pairo-Castineira E, Drivas TG, Peloso GM, et al. Multi-ancestry fine mapping implicates OAS1 splicing in risk of severe COVID-19. Nat Genet. 2022;54(2):125–7.CrossRefPubMedPubMedCentral Huffman JE, Butler-Laporte G, Khan A, Pairo-Castineira E, Drivas TG, Peloso GM, et al. Multi-ancestry fine mapping implicates OAS1 splicing in risk of severe COVID-19. Nat Genet. 2022;54(2):125–7.CrossRefPubMedPubMedCentral
Metadata
Title
Angiotensin-converting enzyme 2 (ACE2) polymorphisms and susceptibility of severe SARS-CoV-2 in a subset of Pakistani population
Authors
Santosh Kumar Sidhwani
Talat Mirza
Ambrina Khatoon
Fouzia Shaikh
Rizma Khan
Omer Ahmed Shaikh
Abdulqadir J. Nashwan
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2023
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/s12985-023-02091-2

Other articles of this Issue 1/2023

Virology Journal 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.